Clinical Trial Update: Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates for dose-escalation of RMC4630 with cobi in relapsed/refractory solid tumors and RMC4630 with osi in EGFR+ locally advanced/metastatic N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Cobi (cobi)
• Osi (osi)
• RMC4630 (RMC4630)

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-26